Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

23.51

Margin Of Safety %

Put/Call OI Ratio

0.25

EPS Next Q Diff

-0.04

EPS Last/This Y

-0.52

EPS This/Next Y

-0.54

Price

23.94

Target Price

95.44

Analyst Recom

1.22

Performance Q

-26.47

Relative Volume

1.07

Beta

0.79

Ticker: VKTX



21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-03-21VKTX28.920.290.43203797
2025-03-24VKTX29.30.290.19160326
2025-03-25VKTX27.990.280.14170593
2025-03-26VKTX26.340.280.18177529
2025-03-27VKTX26.130.270.11193975
2025-03-28VKTX25.630.270.25197873
2025-03-31VKTX24.140.270.08194576
2025-04-01VKTX23.710.270.12199685
2025-04-02VKTX25.690.270.15200797
2025-04-03VKTX24.10.260.24208928
2025-04-04VKTX22.610.260.48210306
2025-04-07VKTX21.260.260.27204214
2025-04-08VKTX19.990.260.22206808
2025-04-09VKTX23.080.260.23207824
2025-04-10VKTX21.520.250.25210131
2025-04-11VKTX22.210.250.14210865
2025-04-14VKTX24.520.260.06200979
2025-04-15VKTX23.10.250.75209191
2025-04-16VKTX23.580.250.09216619
2025-04-17VKTX23.890.250.12222745
2025-04-18VKTX23.940.250.12222745
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1



21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-03-21VKTX28.92-21.9-58.4-1.55
2025-03-24VKTX29.28-21.9-56.1-1.55
2025-03-25VKTX27.98-21.9-40.2-1.55
2025-03-26VKTX26.34-21.9-35.9-1.55
2025-03-27VKTX26.11-21.9-50.1-1.55
2025-03-28VKTX25.65-21.9-47.3-1.55
2025-03-31VKTX24.15-21.9-35.4-1.55
2025-04-01VKTX23.91-21.9-50.0-1.55
2025-04-02VKTX25.68-21.9-75.3-1.55
2025-04-03VKTX24.22-21.9-35.8-1.55
2025-04-04VKTX22.62-21.9-32.6-1.55
2025-04-07VKTX21.24-21.9-33.5-1.55
2025-04-08VKTX19.98-21.9-33.0-1.55
2025-04-09VKTX23.10-21.9-106.5-1.55
2025-04-10VKTX21.52-19.7-31.8-1.53
2025-04-11VKTX22.21-19.7-62.9-1.53
2025-04-14VKTX24.57-19.7-86.5-1.53
2025-04-15VKTX23.11-19.7-34.7-1.53
2025-04-16VKTX23.62-19.7-59.5-1.53
2025-04-17VKTX23.94-19.7-57.2-1.53
2025-04-18VKTX23.94-19.7-52.7-1.53
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1



21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-03-21VKTX-12.230.4421.95
2025-03-24VKTX-12.230.4621.95
2025-03-25VKTX-12.230.4621.95
2025-03-26VKTX-12.230.4622.23
2025-03-27VKTX-12.230.4622.23
2025-03-28VKTX-12.230.4622.23
2025-03-31VKTX-12.230.4422.23
2025-04-01VKTX-12.230.4422.23
2025-04-02VKTX-12.230.4422.23
2025-04-03VKTX-12.200.4422.23
2025-04-04VKTX-12.200.4422.23
2025-04-07VKTX-12.200.4622.23
2025-04-08VKTX-12.200.4622.23
2025-04-09VKTX-12.200.4622.23
2025-04-10VKTX-12.200.4623.51
2025-04-11VKTX-12.200.4623.51
2025-04-14VKTX-12.200.4623.51
2025-04-15VKTX-12.200.4623.51
2025-04-16VKTX-12.190.4623.51
2025-04-17VKTX-12.190.4623.51
2025-04-18VKTX-12.190.4623.51
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS​

-0.32

Avg. EPS Est. Current Quarter

-0.32

Avg. EPS Est. Next Quarter

-0.36

Insider Transactions

-12.19

Institutional Transactions

0.46

Beta

0.79

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

12

Growth Score

25

Sentiment Score

65

Actual DrawDown %

75.9

Max Drawdown 5-Year %

-78.9

Target Price

95.44

P/E

Forward P/E

PEG

P/S

P/B

3.03

P/Free Cash Flow

EPS

-1.01

Average EPS Est. Cur. Y​

-1.53

EPS Next Y. (Est.)

-2.07

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1.07

Return on Equity vs Sector %

-32.5

Return on Equity vs Industry %

-19.1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.02

EBIT Estimation

-52.7
Viking Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 36
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
stock quote shares VKTX – Viking Therapeutics, Inc. Stock Price stock today
news today VKTX – Viking Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VKTX – Viking Therapeutics, Inc. yahoo finance google finance
stock history VKTX – Viking Therapeutics, Inc. invest stock market
stock prices VKTX premarket after hours
ticker VKTX fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Facebook-f Twitter Tiktok Instagram Youtube

Get Started

About